ID: ALA270304

Max Phase: Preclinical

Molecular Formula: C31H52N4O2

Molecular Weight: 512.78

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCCCCCCCCCCCCCN1CCN(Cc2ccc(-c3noc(=O)[nH]3)cc2)CC1

Standard InChI:  InChI=1S/C31H52N4O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-22-34-23-25-35(26-24-34)27-28-18-20-29(21-19-28)30-32-31(36)37-33-30/h18-21H,2-17,22-27H2,1H3,(H,32,33,36)

Standard InChI Key:  ORLPULOZISVXAZ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 512.78

Molecular Weight (Monoisotopic): 512.4090

AlogP: 7.41

#Rotatable Bonds: 20

Polar Surface Area: 65.37

Molecular Species: ACID

HBA: 5

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 5.90

CX Basic pKa: 8.37

CX LogP: 7.68

CX LogD: 7.73

Aromatic Rings: 2

Heavy Atoms: 37

QED Weighted: 0.19

Np Likeness Score: -0.85

References

1. Boukli L, Touaibia M, Meddad-Belhabich N, Djimdé A, Park CH, Kim JJ, Yoon JH, Lamouri A, Heymans F..  (2008)  Design of new potent and selective secretory phospholipase A2 inhibitors. Part 5: synthesis and biological activity of 1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-5-one-3-ylmethylbenz-4'-yl(oyl)] piperazines.,  16  (3): [PMID:17993277] [10.1016/j.bmc.2007.10.077]

2. Meddad-Belhabich N, Aoun D, Djimdé A, Redeuilh C, Dive G, Massicot F, Chau F, Heymans F, Lamouri A..  (2010)  Design of new potent and selective secretory phospholipase A(2) inhibitors. 6-Synthesis, structure-activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/dione derivatives.,  18  (10): [PMID:20417107] [10.1016/j.bmc.2010.03.049]

Source

Source(1):

• Scientific Literature